Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and raises the price target from $30 to $31.
July 11, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a 'Buy' rating on 4D Molecular Therapeutics and raises the price target from $30 to $31.
The 'Buy' rating maintained by Chardan Capital indicates a positive outlook for 4D Molecular Therapeutics. The increase in price target from $30 to $31 suggests that the analyst sees potential for the stock's price to rise in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100